Loading...
XNYSABT
Market cap198bUSD
Dec 20, Last price  
114.23USD
1D
1.61%
1Q
0.47%
Jan 2017
197.40%
Name

Abbott Laboratories

Chart & Performance

D1W1MN
XNYS:ABT chart
P/E
34.62
P/S
4.94
EPS
3.30
Div Yield, %
1.79%
Shrs. gr., 5y
-0.24%
Rev. gr., 5y
5.58%
Revenues
40.11b
-8.12%
19,680,016,00022,337,808,00022,476,322,00025,914,238,00029,527,552,00030,765,000,00035,167,000,00038,851,000,00039,874,000,00021,848,000,00020,247,000,00020,405,000,00020,853,000,00027,390,000,00030,578,000,00031,904,000,00034,608,000,00043,075,000,00043,653,000,00040,109,000,000
Net income
5.72b
-17.45%
3,235,851,0003,372,065,0001,716,755,0003,606,314,0004,880,719,0005,745,838,0004,626,172,0004,728,000,0005,963,000,0002,576,000,0002,284,000,0004,423,000,0001,400,000,000477,000,0002,368,000,0003,687,000,0004,495,000,0007,071,000,0006,933,000,0005,723,000,000
CFO
7.26b
-24.21%
4,407,943,0005,174,416,0005,329,241,0005,183,843,0007,344,191,0007,275,160,0008,735,981,0008,970,077,0009,314,401,0003,324,000,0003,675,000,0002,966,000,0003,203,000,0005,570,000,0006,300,000,0006,136,000,0007,901,000,00010,533,000,0009,581,000,0007,261,000,000
Dividend
Oct 15, 20240.55 USD/sh
Earnings
Jan 22, 2025

Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
URL
https://www.abbott.com/
IPO date
Mar 01, 1937
Employees
115,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
40,109,000
-8.12%
43,653,000
1.34%
43,075,000
24.47%
Cost of revenue
20,716,000
22,030,000
21,279,000
Unusual Expense (Income)
NOPBT
19,393,000
21,623,000
21,796,000
NOPBT Margin
48.35%
49.53%
50.60%
Operating Taxes
941,000
1,373,000
1,140,000
Tax Rate
4.85%
6.35%
5.23%
NOPAT
18,452,000
20,250,000
20,656,000
Net income
5,723,000
-17.45%
6,933,000
-1.95%
7,071,000
57.31%
Dividends
(3,556,000)
(3,309,000)
(3,202,000)
Dividend yield
1.85%
1.71%
1.27%
Proceeds from repurchase of equity
(1,227,000)
(3,628,000)
(2,044,000)
BB yield
0.64%
1.87%
0.81%
Debt
Debt current
1,325,000
2,251,000
754,000
Long-term debt
15,497,000
16,408,000
19,208,000
Deferred revenue
2,738,000
Other long-term liabilities
5,998,000
5,588,000
3,685,000
Net debt
8,744,000
7,723,000
8,897,000
Cash flow
Cash from operating activities
7,261,000
9,581,000
10,533,000
CAPEX
(2,202,000)
(1,777,000)
(1,885,000)
Cash from investing activities
(3,133,000)
(1,740,000)
(2,008,000)
Cash from financing activities
(7,091,000)
(7,636,000)
(5,494,000)
FCF
17,450,000
17,207,000
20,693,000
Balance
Cash
7,279,000
10,170,000
10,249,000
Long term investments
799,000
766,000
816,000
Excess cash
6,072,550
8,753,350
8,911,250
Stockholders' equity
54,808,000
52,134,000
47,846,000
Invested Capital
54,625,450
51,112,650
52,235,750
ROIC
34.90%
39.19%
39.31%
ROCE
31.95%
35.53%
34.85%
EV
Common stock shares outstanding
1,749,000
1,764,000
1,789,000
Price
110.07
0.26%
109.79
-21.99%
140.74
28.54%
Market cap
192,512,430
-0.60%
193,669,560
-23.08%
251,783,860
28.76%
EV
201,480,430
201,611,560
260,902,860
EBITDA
22,636,000
24,890,000
25,334,000
EV/EBITDA
8.90
8.10
10.30
Interest
637,000
375,000
490,000
Interest/NOPBT
3.28%
1.73%
2.25%